Pharma BD Deal Intelligence
Servier acquires Symphogen gaining Danish biotech antibody discovery capabilities for recombinant antibody mixtures in oncology pipeline
Servier completes acquisition of Symphogen gaining next-generation antibody technologies and pipeline of oncology therapeutic candidates
Servier completes the acquisition of Symphogen establishing antibody center of excellence for oncology and immuno-oncology development
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Servier acquired Symphogen, a leading antibody discovery company.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier / Symphogen A/S (this deal) | 2006 | — | 66 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| Servier / Edgewise Therapeutics, Inc. | 2026 | $2.6B | 75 |
| Servier / Symphogen A/S | 2020 | — | — |
| Servier / Pieris Pharmaceuticals, Inc. | 2017 | $1.7B | — |
| Servier / IDEAYA Biosciences, Inc. | 2025 | $530M | — |
← Browse all deals · How we score deals
More: 2006 deals · Servier deals · Oncology deals